

VOLUMEN XLIX

NUMERUS suppl 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2021

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Petar Suton – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Marija Pastorčić-Grgić, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Sanda Šitić, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), B.I. Šikić (Stanford, USA), I. Tomaš (Osijek, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA), M. Zovak (Zagreb, Croatia).

Indexed in SCOPUS and EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb

REKOG

BOSNA I HERCEGOVINA
CRNA GORA
HRVATSKA
SLOVENIJA
SRBIJA
REGIONALNA KOOPERATIVNA
ONKOLOŠKA GRUPA



BOSNA I HERCEGOVINA
CRNA GORA
HRVATSKA
SLOVENIJA
SRBIJA
REKOG
REGIONALNA KOOPERATIVNA
ONKOLOŠKA GRUPA

REKOG

BOSNA I HERCEGOVINA
CRNA GORA
HRVATSKA
SLOVENIJA
SRBIJA
REGIONALNA KOOPERATIVNA
ONKOLOŠKA GRUPA



BOSNA I HERCEGOVINA
CRNA GORA
HRVATSKA
SLOVENIJA
SRBIJA
REKOG
REGIONALNA KOOPERATIVNA
ONKOLOŠKA GRUPA

**3th REGIONAL CONGRESS
OF MEDICAL ONCOLOGY
III. REGIONALNI KONGRES
INTERNISTIČKE ONKOLOGIJE
/REKONIO/**

07. – 09. MAY 2021. Sarajevo
VIRTUAL CONGRESS

Supplement editor:
Robert Šeparović

Zagreb, Croatia
May, 2021

ORGANIZER

Regional Cooperative Oncology Group
(Regionalna kooperativna onkološka grupa)
Association of Oncologists in Bosnia and Herzegovina
(Udruženje onkologa Bosne i Hercegovine)

INTERNATIONAL ORGANIZING COMMITTEE

Borislav Belev
Ivan Nikolić
Jana Ocvirk
Lazar Popović
Siniša Radulović
Davorin Radosavljević
Robert Šeparović
Vladimir Todorović
Damir Vrbanec
Bojan Zarić

LOCAL ORGANIZING COMMITTEE

Semir Bešlija /president/
Timur Cerić
Maja Banjin
Anes Pašić
Elma Kapisazović
Emina Borovac Gurda
Emir Sokolović

Contents

ORAL PRESENTATIONS

Lejla Alidžanović Nurkanović, Dalma Udovičić-Gagula S1 - The power of pathology - influence of mutational status in NSCLC on oncological treatment	3
Katarina Antunac S2 - Radiotherapy of CNS metastases	4
Borislav Belev S3 - The role of immunotherapy in metastatic colorectal cancer treatment - is there a room for improvement?	5
Emina Bičakčić Filipović, Elma Kapisazović S4 - The best approach to systemic therapy in first line treatment of advanced/metastatic HCC	6
Simona Borštnar S5 - PARP inhibitors in the treatment of triple negative breast cancer	8
Timur Cerić, Anes Pašić, Emina Bičakčić-Filipović, Elma Kapisazović, Mujo Kadrić, Emir Sokolović, Emina Borovac-Gurda, Semir Bešlija S6 - ALK /ROS1 and beyond: Novel molecularly driven targeted therapies in with non-small cell lung cancer (NSCLC)	9
Natalija Dedić Plavetić S7 - Optimal sequence in HER-2 positive metastatic breast cancer	11
Lidija Kandolf Sekulović S8 - An unmet need in BRAF mutant metastatic melanoma: treatment sequencing and leptomeningeal disease	13
Suzana Matković S9 - Urinary bladder carcinoma	14
Tanja Mesti S10 - Next generation sequencing	15
Ivana Minić, Zorica Tomašević S11 - Do all patients with recurrent ovarian cancer need systemic therapy and which is the optimal treatment algorithm	16
Janja Ocvirk S12 - Systemic treatment of melanoma	18

Anes Pašić, Elma Kapisazović	
S13 - Treatment of HER2 positive gastric cancer	19
Radmila Rašeta, Tamara Višekruna, Živko Vranješ, Zdenka Gojković, Milka Vještica, Dejan Đokanović	
S14 - State of the art in treatment of mRC: a case report	21
Tajana Silovski, Nikolina Lonjak, Sanda Šitić	
S15 - PARP inhibitors in the treatment of the ovarian cancer	22
Robert Šeparović	
S16 - Head and neck carcinoma	24
Boštjan Šeruga	
S17 - PARP inhibitors in the treatment of prostate cancer	26
Ana Tečić Vuger	
S18 – Value of antiHER2 treatment in breast cancer	27
Ana Tečić Vuger	
S19 - Adjuvant antihormonal treatment of early breast cancer	29
Vladimir Todorović	
S20 - Optimal sequence in hormon receptor positive metastatic breast cancer	30
Ljubica Vazdar	
S21 - CNS metastases in HER2 positive and triple negative disease	31
Damir Vrbanec, Davorin Radosavljević	
S22 - Top ten news (except COVID) in 2020 oncology	33

POSTER PRESENTATIONS

Renata Kelemenić-Dražin, Anuška Budisavljević	
P1 - Application of arteficial intelligence in personalized treatment of oncology patients	37
Jurica Vrbanec, Lidija Kocić, Dragan Trivanović	
P2 - Application of chemotherapy via elastomeric pump in an outpatient setting: patient satisfaction survey	39
Petra Lepetić, Petra Linarić, Dejana Jezernik, Kristina Kanceljak, Ana Tečić Vuger, Mirjana Pavlović, Ljubica Vazdar, Robert Šeparović	
P3 - Assessment of fatigue in cancer patients treated with ribociclib and endocrine therapy according to patient reported outcomes at the University Hospital for Tumors	40
Lazar Popović, Maja Popović, Maša Jović, Gorana Matovina Brko	
P4 - Atezolizumab in the second line treatment of metastatic urothelial cancer the first experience outside of clinical trial	41
Mirjana Pavlović, Robert Šeparović, Ljubica Vazdar, Ana Tečić Vuger, Petra Lepetić, Petra Linarić	
P5 - Body composition of breast cancer patients treated with adjuvant chemotherapy and its influence on quality of life	42

Emina Borovac-Gurda, Benjamin Bećirević	
P6 – BRAF positive malignant melanoma: case report	43
Ljubica Vazdar, Mirjana Pavlović, Ana Tečić Vuger, Petra Lepetić, Petra Linarić, Robert Šeparović	
P7 - Cardiac safety of palbociclib in breast cancer patients with cardiac risk	45
Berisa Hasanbegović, Emir Sokolović, Benjamin Bećirević	
P8 - Case of reccurent uterine adenosarcoma with sarcomatous overgrowth (ASSO)	46
Ana Tečić Vuger, Robert Šeparović, Ljubica Vazdar, Mirjana Pavlović, Sanda Šitić, Petra Lepetić, Petra Linarić, Damir Vrbanec	
P9 - Clinical value of androgen receptors in triple negative breast cancer	48
Jelena Oblaković-Babić, Ivana Božović-Spasojević	
P10 - Comparison of pathological response in HER2 positive breast cancer, mono versus dual anti-HER2 blockade, data from clinical practice	49
Ognjen Djurmez, Marina Čalamac, Marija Dimitrijević, Jelena Oblaković-Babić, Ivana Minić, Zoran Tomašević, Ivana Božović-Spasojević	
P11 - COVID-19 vaccination in patients with cancer – single institutional expreience	50
Hrvoje Silovski, Ivan Romić, Ante Gojević, Tomislav Baotić, Igor Petrović, Ognjan Deban, Goran Pavlek, Ivan Šeparović, Jurica Žedelj, Iva Martina Strajher, Boško Romić	
P12 - Current strategies to improve resectability of colorectal liver metastases	52
Maja Popović, Gorana Matovina Brko, Maša Jović, Jasna Pešić, Jasna Trifunović, Lazar Popović	
P13 - Dual blockade with pertuzumab/trastuzumab versus trastuzumab in neoadjuvant treatment of HER2 positive breast cancer	53
Vladimir Nikolić, Nemanja Stanić, Marija Ristić, Neda Nikolić, Jelena Spasić, Feđa Đorđević, Davorin Radosavljević	
P14 - Efficacy of biweekly cetuximab-irinotecan combination in third line treatment of patients with metastatic colorectal cancer	54
Gorana Matovina Brko, Maja Popović, Jasna Trifunović, Jasna Pešić, Lazar Popović	
P15 - Endocrine versus chemotherapy in metastatic HR+/HER2- breast cancer	55
Emir Sokolović, Mujo Kadrić	
P16 - Gastric metastasis 15 years after radical mastectomy for primary breast cancer - case report	56
Maja Popović, Gorana Matovina Brko, Maša Jović, Lazar Popović	
P17 - Hyperprogressive disease in patient with metastatic urothelial carcinoma treated with atezolizumab – case report	57
Ana Koši Kunac, Milena Gnjidić, Borislav Belev	
P18 - Kidney cancer: how could we interpret radiologic response to immunotherapy?	58
Petra Linarić, Ana Tečić Vuger, Ljubica Vazdar, Mirjana Pavlović, Petra Lepetić, Robert Šeparović	
P19 - Neoadjuvant treatment for HER2 positive early breast cancer – differences between trastuzumab monotherapy and dual anti-HER2 blockade in our clinical practice	59

Emina Borovac-Gurda, Emina Bičakčić-Filipović P20 - Pathological complete response following neoadjuvant therapy for gastric carcinoma	61
Simonida Bobic, Lidija Pavlović, Andjela Karaferić, Marijana Milović-Kovačević, Ljiljana Stamatović P21 - Pathological complete response rates with dual HER2 blockade added to neoadjuvant chemotherapy in breast cancer: a single-center experience	63
Domina Kekez, Borislav Belev P22 - Patient with liver tumore before and after liver transplantation	64
Marija Milosavljević, Suzana Matković, Nada Babović, Tamara Ursulović P23 - Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for squamocellular head and neck cancer	65
Marija Dimitrijević, Ognjen Djurmez, Marina Čalamac, Kristina Šerović, Jelena Oblaković, Ivana Minic, Zoran Tomašević, Ivana Božović-Spasojević P24 - Side effects of LHRH analogues in the treatment of early breast cancer patients: frequency and timing	66
Aleksandar Popović, Ivan Petković, Aleksandra Dimitrijević, Stefan Stankov, Ivica Pejčić, Svetislav Vrbić P25 - Single center experience study with pembrolizumab in patients with unresectable or metastatic melanoma	67
Fedja Djordjević, Jelena Dimitrijević, Marina Čalamac, Ana Žilić, Nataša Lazin, Snežana Šušnjar, Vesna Stanković, Snežana Bošnjak P26 - The model of a direct collaboration between multidisciplinary tumor board and supportive care department for patients with advanced cancer	68
Lidija Pavlović, Simonida Bobic, Andjela Karaferić, Marijana Milović-Kovačević, Ljiljana Stamatović P27 - Tolerability of olaparib in patients with BRCA 1/2-mutated platinum-sensitive recurrent high-grade serous ovarian cancer receiving olaparib maintenance monotherapy: a single institution experience	69
Marija Kraljević, Elma Kapisazović, Teo Buhovac, Inga Marijanović, Anes Pašić, Emina Bičakčić – Filipović P28 - Treatment of a patient with advanced hepatocellular carcinoma - case report . . .	70
Neda Nikolić, Nemanja Stanić, Jelena Spasić, Vladimir Nikolić, Feđa Đorđević, Davorin Radosavljević P29 - Young-onset colorectal cancer	71
AUTHOR INDEX	73